Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Gray Sheet

Executive Summary

Tissue processing firm's interim agreement with FDA permitting continued distribution of its non-valved cardiac and vascular tissues is extended to June 13, CryoLife announces March 19. The agreement previously was set to expire March 20 (1"The Gray Sheet" Feb. 3, 2003, p. 22). CryoLife is preparing its response to FDA concerns stemming from a recent inspection, outlined in a 483 report, which largely relate to complaint handling, according to the company (2"The Gray Sheet" March 10, 2003, p. 29)...

You may also be interested in...

CryoLife Rebuilds Processing Capacity, Eyes Profitability After FDA Reprieve

CryoLife credits San Francisco-based Acumen Sciences for guiding it through an FDA Form 483 and a subsequent recall of cardiac, orthopedic and vascular tissue products

CryoLife, FDA Extend Interim Operating Agreement To March 20

CryoLife anticipates filing an investigational device exemption submission with FDA to expand the indication of BioGlue for the sealing of dura mater by late 2003

Surprise As FDA Approves Sarepta’s Duchenne Drug Vyondys 53

The FDA has overcome doubts about the drug's safety and reversed its decision in just four months.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts